养老院居民使用胆碱酯酶抑制剂时抗胆碱能药物共处方:潜在的处方瀑布逆转
该回顾性分析利用2015至2016年多源数据,纳入≥65岁严重痴呆养老院居民,发现15%存在抗胆碱能药与胆碱酯酶抑制剂共处方,女性、多重用药及非老年科处方者增加共处方风险,停用胆碱酯酶抑制剂与后续停用抗胆碱能药的风险降低相关(HR 0.58)。
要点
- 严重痴呆养老院居民中15%存在抗胆碱能药与胆碱酯酶抑制剂共处方。
- 女性、多重用药和非老年科处方者与更高共处方风险相关。
- 停用胆碱酯酶抑制剂与后续停用抗胆碱能药风险降低相关(HR 0.58)。
核心结论
- 较年轻、较健康的痴呆老人更易出现抗胆碱能药与胆碱酯酶抑制剂共处方,且抗胆碱能药停用不常见。
研究设计与样本
- 回顾性分析2015至2016年连接Medicare Part A/B/D索赔、Master Beneficiary Summary File、Minimum Data Set、Area Health Resource File及Nursing Home Compare数据。
- 研究对象为居住养老院、≥65岁、严重痴呆、非技能护理住院且处方胆碱酯酶抑制剂的Medicare受益人。
主要发现
- 样本中15%经历抗胆碱能药与胆碱酯酶抑制剂共处方。
- 高龄、少数种族或族裔、终末期肾病、心力衰竭和食欲差与共处方可能性降低相关。
- 女性、多重用药和非老年科处方者类型与共处方可能性升高相关。
- 停用胆碱酯酶抑制剂与停用任何抗胆碱能特性药物可能性降低相关(HR 0.58 [95% CI, 0.47-0.71]),但膀胱抗毒蕈碱药除外(HR 1.32 [95% CI, 0.83-2.09])。
临床怎么用
- 对使用胆碱酯酶抑制剂的严重痴呆养老院居民,应警惕抗胆碱能药共处方及处方瀑布。
- 考虑停用胆碱酯酶抑制剂时,可评估后续停用抗胆碱能药的可能性以逆转处方瀑布。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy may result from inappropriate prescribing of medications to treat adverse drug reactions (ADRs), i.e., "prescribing cascade." A potentially harmful prescribing cascade affecting those with severe dementia can result when anticholinergics are prescribed to manage side effects of cholinesterase inhibitors (ChEIs). We investigated 1) factors associated with co-prescribing of anticholinergics and ChEIs and 2) whether discontinuation of ChEIs was associated with subsequent discontinuation of anticholinergics-a potentially beneficial reversal or "deprescribing cascade." METHODS: We conducted a retrospective analysis of linked Medicare Part A/B/D claims, Master Beneficiary Summary File, Minimum Data Set, Area Health Resource File, and Nursing Home Compare from 2015 to 2016. Subjects were Medicare beneficiaries residing in nursing homes, ≥65 years old with severe dementia admitted for non-skilled stays, who were prescribed ChEIs. Cross-sectional analysis evaluated factors associated with co-prescribing of anticholinergics with ChEIs. Longitudinal Cox proportional hazards regression examined whether discontinuation of ChEIs was associated with subsequent discontinuation of anticholinergics over a 1-year period. RESULTS: We found 15% of our sample experienced co-prescribing of anticholinergics and ChEIs. Several resident and facility-level factors were associated with co-prescribing anticholinergics. Advancing age, minority race or ethnicity, end-stage renal disease, heart failure, and poor appetite were associated with a decreased likelihood of co-prescribing. Female sex, polypharmacy, and non-geriatric prescriber-type were associated with a higher likelihood of co-prescribing. In longitudinal analyses, we observed that discontinuation of ChEIs was associated with a reduced likelihood (HR 0.58 [95% CI, 0.47-0.71]) of discontinuing any medications with anticholinergic properties, except for bladder antimuscarinics (HR 1.32 [95% CI, 0.83-2.09]). CONCLUSIONS: Younger, healthier older adults with dementia were more likely to experience co-prescribing anticholinergics and ChEIs. Discontinuation of anticholinergics was infrequent. Further research is needed to understand prescribers' ability to recognize and reverse potential prescribing cascades through deprescribing.
引用
- Gromek KR, Thorpe CT, Aspinall SL, et al. Anticholinergic co-prescribing in nursing home residents using cholinesterase inhibitors: Potential deprescribing cascade. J Am Geriatr Soc. 2022. PMID: 36206324. doi:10.1111/jgs.18066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。